Medical Economics January 17, 2025
Key Takeaways
- Medicare will negotiate prices for Ozempic, Wegovy, and Rybelsus, targeting cost reductions for expensive drugs.
- The Inflation Reduction Act empowers these negotiations, aiming to improve drug affordability for seniors.
- Pharmaceutical companies must decide by February 28 to participate in negotiations, with new prices effective in 2027.
- The initiative seeks to save billions and enhance Medicare’s sustainability for future generations.
New prices would take effect in 2027.
Ozempic (semaglutide), the Type 2 diabetes drug that has become popular for weight loss, and Wegovy, the form of the drug approved for patients to shed pounds, are on the list for Medicare drug price negotiations in 2025.
Rybelsus, the oral form of semaglutide, also is on the list announced...
Today's Sponsors
Today's Sponsor